<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31915195</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>06</Month>
        <Day>09</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>11</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2159-8290</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>10</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Cancer discovery</Title>
          <ISOAbbreviation>Cancer Discov</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia.</ArticleTitle>
        <Pagination>
          <StartPage>394</StartPage>
          <EndPage>405</EndPage>
          <MedlinePgn>394-405</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1158/2159-8290.CD-19-1130</ELocationID>
        <Abstract>
          <AbstractText>Acalabrutinib is a selective irreversible Bruton tyrosine kinase (BTK) inhibitor that does not affect IL2-associated tyrosine kinase or antibody-dependent cellular cytotoxicity, making it an attractive candidate for combination therapy with anti-CD20 antibodies. We investigated acalabrutinib plus obinutuzumab in a phase Ib/II study (NCT02296918) of patients with treatment-naïve or relapsed/refractory chronic lymphocytic leukemia (CLL). Nineteen treatment-naïve and 26 relapsed/refractory patients were treated with acalabrutinib (100 mg twice daily) until progression and obinutuzumab (cycle 1: 100 mg day 1, 900 mg day 2, 1000 mg days 8 and 15; cycles 2-6: 1,000 mg day 1). Grade 3/4 adverse events occurred in 71% of patients. Overall response rates were 95% (treatment-naïve) and 92% (relapsed/refractory). Thirty-two percent of treatment-naïve and 8% of relapsed/refractory patients achieved complete remission. At 36 months, 94% (treatment-naïve) and 88% (relapsed/refractory) were progression free. Acalabrutinib plus obinutuzumab was well tolerated, producing high and durable responses in treatment-naïve and relapsed/refractory CLL. SIGNIFICANCE: Rituximab plus the less selective BTK inhibitor ibrutinib has not shown benefit in CLL; however, the selective BTK inhibitor acalabrutinib plus the antibody-dependent cellular cytotoxicity-enhanced antibody obinutuzumab yielded durable responses that deepened over time in treatment-naïve and relapsed/refractory CLL, supporting the evaluation of this approach in larger, comparative studies in CLL.<i>This article is highlighted in the In This Issue feature, p. 327</i>.</AbstractText>
          <CopyrightInformation>©2020 American Association for Cancer Research.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Woyach</LastName>
            <ForeName>Jennifer A</ForeName>
            <Initials>JA</Initials>
            <AffiliationInfo>
              <Affiliation>The Ohio State University Comprehensive Cancer Center, Columbus, Ohio. jennifer.woyach@osumc.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Blachly</LastName>
            <ForeName>James S</ForeName>
            <Initials>JS</Initials>
            <Identifier Source="ORCID">0000-0002-4275-5562</Identifier>
            <AffiliationInfo>
              <Affiliation>The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rogers</LastName>
            <ForeName>Kerry A</ForeName>
            <Initials>KA</Initials>
            <AffiliationInfo>
              <Affiliation>The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bhat</LastName>
            <ForeName>Seema A</ForeName>
            <Initials>SA</Initials>
            <AffiliationInfo>
              <Affiliation>The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jianfar</LastName>
            <ForeName>Mojgan</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lozanski</LastName>
            <ForeName>Gerard</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Weiss</LastName>
            <ForeName>David M</ForeName>
            <Initials>DM</Initials>
            <AffiliationInfo>
              <Affiliation>The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Andersen</LastName>
            <ForeName>Barbara L</ForeName>
            <Initials>BL</Initials>
            <Identifier Source="ORCID">0000-0002-7335-1325</Identifier>
            <AffiliationInfo>
              <Affiliation>The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gulrajani</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Acerta Pharma, a member of the AstraZeneca Group, South San Francisco, California.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Frigault</LastName>
            <ForeName>Melanie M</ForeName>
            <Initials>MM</Initials>
            <AffiliationInfo>
              <Affiliation>Acerta Pharma, a member of the AstraZeneca Group, South San Francisco, California.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hamdy</LastName>
            <ForeName>Ahmed</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Acerta Pharma, a member of the AstraZeneca Group, South San Francisco, California.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Izumi</LastName>
            <ForeName>Raquel</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Acerta Pharma, a member of the AstraZeneca Group, South San Francisco, California.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Munugalavadla</LastName>
            <ForeName>Veerendra</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Acerta Pharma, a member of the AstraZeneca Group, South San Francisco, California.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Quah</LastName>
            <ForeName>Cheng</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Acerta Pharma, a member of the AstraZeneca Group, South San Francisco, California.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Min-Hui</ForeName>
            <Initials>MH</Initials>
            <AffiliationInfo>
              <Affiliation>Acerta Pharma, a member of the AstraZeneca Group, South San Francisco, California.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Byrd</LastName>
            <ForeName>John C</ForeName>
            <Initials>JC</Initials>
            <AffiliationInfo>
              <Affiliation>The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>ClinicalTrials.gov</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>NCT02296918</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>P30 CA016058</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA197870</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R35 CA197734</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType>
          <PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>01</Month>
          <Day>08</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Cancer Discov</MedlineTA>
        <NlmUniqueID>101561693</NlmUniqueID>
        <ISSNLinking>2159-8274</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001549">Benzamides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C508594">IL2 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007376">Interleukin-2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011719">Pyrazines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>4F4X42SYQ6</RegistryNumber>
          <NameOfSubstance UI="D000069283">Rituximab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.2</RegistryNumber>
          <NameOfSubstance UI="D000077329">Agammaglobulinaemia Tyrosine Kinase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.2</RegistryNumber>
          <NameOfSubstance UI="C000625949">BTK protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>I42748ELQW</RegistryNumber>
          <NameOfSubstance UI="C000604908">acalabrutinib</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>O43472U9X8</RegistryNumber>
          <NameOfSubstance UI="C543332">obinutuzumab</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077329" MajorTopicYN="N">Agammaglobulinaemia Tyrosine Kinase</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001549" MajorTopicYN="N">Benzamides</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007376" MajorTopicYN="N">Interleukin-2</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015451" MajorTopicYN="N">Leukemia, Lymphocytic, Chronic, B-Cell</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011719" MajorTopicYN="N">Pyrazines</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069283" MajorTopicYN="N">Rituximab</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>9</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31915195</ArticleId>
        <ArticleId IdType="mid">NIHMS1704392</ArticleId>
        <ArticleId IdType="pmc">PMC8176161</ArticleId>
        <ArticleId IdType="doi">10.1158/2159-8290.CD-19-1130</ArticleId>
        <ArticleId IdType="pii">2159-8290.CD-19-1130</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S, et al.
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood
2011;117:6287–96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3122947</ArticleId>
            <ArticleId IdType="pubmed">21422473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herman SE, Mustafa RZ, Gyamfi JA, Pittaluga S, Chang S, Chang B, et al.
Ibrutinib inhibits BCR and NF-kappaB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL. Blood
2014;123:3286–95.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4046423</ArticleId>
            <ArticleId IdType="pubmed">24659631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herman SE, Mustafa RZ, Jones J, Wong DH, Farooqui M, Wiestner A. Treatment with ibrutinib inhibits BTK- and VLA-4-dependent adhesion of chronic lymphocytic leukemia cells in vivo. Clin Cancer Res
2015;21:4642–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4609275</ArticleId>
            <ArticleId IdType="pubmed">26089373</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Woyach JA, Smucker K, Smith LL, Lozanski A, Zhong Y, Ruppert AS, et al.
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood
2014;123:1810–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3962160</ArticleId>
            <ArticleId IdType="pubmed">24415539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Gorter DJ, Beuling EA, Kersseboom R, Middendorp S, van Gils JM, Hendriks RW, et al.
Bruton’s tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing. Immunity
2007;26:93–104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17239630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Rooij MF, Kuil A, Geest CR, Eldering E, Chang BY, Buggy JJ, et al.
The clinically active BTK inhibitor PCI-32765 targets B-cell receptor-and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood
2012;119:2590–4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22279054</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG, et al.
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood
2012;119:1182–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4916557</ArticleId>
            <ArticleId IdType="pubmed">22180443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Byrd JC, Brown JR, O’Brien S, Barrientos JC, Kay NE, Reddy NM, et al.
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med
2014;371:213–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4134521</ArticleId>
            <ArticleId IdType="pubmed">24881631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al.
Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med
2015;373:2425–37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4722809</ArticleId>
            <ArticleId IdType="pubmed">26639149</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, et al.
Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med
2018;379:2517–28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6325637</ArticleId>
            <ArticleId IdType="pubmed">30501481</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shanafelt TD, Wang XV, Kay NE, Hanson CA, O’Brien S, Barrientos J, et al.
Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med
2019;381:432–43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6908306</ArticleId>
            <ArticleId IdType="pubmed">31365801</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mato AR, Nabhan C, Thompson MC, Lamanna N, Brander DM, Hill B, et al.
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica
2018;103:874–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5927982</ArticleId>
            <ArticleId IdType="pubmed">29419429</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Winkelstein JA, Marino MC, Lederman HM, Jones SM, Sullivan K, Burks AW, et al.
X-linked agammaglobulinemia: report on a United States registry of 201 patients. Medicine
2006;85:193–202.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16862044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Howard V, Greene JM, Pahwa S, Winkelstein JA, Boyle JM, Kocak M, et al.
The health status and quality of life of adults with X-linked agammaglobulinemia. Clin Immunol
2006;118:201–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16377251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Golay J, Ubiali G, Introna M. The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable in vitro activity against chronic lymphocytic leukemia B cells with CD20 antibodies. Haematologica
2017;102:e400–e3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5622871</ArticleId>
            <ArticleId IdType="pubmed">28642301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Byrd JC, Harrington B, O’Brien S, Jones JA, Schuh A, Devereux S, et al.
Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med
2016;374:323–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4862586</ArticleId>
            <ArticleId IdType="pubmed">26641137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barf T, Covey T, Izumi R, van de Kar B, Gulrajani M, van Lith B, et al.
Acalabrutinib (ACP-196): a covalent Bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile. J Pharmacol Exp Ther
2017;363:240–52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28882879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Byrd JC, Wierda W, Schuh A, Devereaux S, Chaves J, Brown JR, et al.
Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated results from the phase 1/2 ACE-CL-001 Study. Blood
2017;130:498.</Citation>
        </Reference>
        <Reference>
          <Citation>O’Brien S, Furman RR, Coutre S, Flinn IW, Burger JA, Blum K, et al.
Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood
2018;131:1910–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5921964</ArticleId>
            <ArticleId IdType="pubmed">29437592</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>VanDerMeid KR, Elliott MR, Baran AM, Barr PM, Chu CC, Zent CS. Cellular cytotoxicity of next-generation CD20 monoclonal antibodies. Cancer Immunol Res
2018;6:1150–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30089638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kohrt HE, Sagiv-Barfi I, Rafiq S, Herman SE, Butchar JP, Cheney C, et al.
Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. Blood
2014;123:1957–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3962169</ArticleId>
            <ArticleId IdType="pubmed">24652965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Da Roit F, Engelberts PJ, Taylor RP, Breij EC, Gritti G, Rambaldi A, et al.
Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy. Haematologica
2015;100:77–86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4281316</ArticleId>
            <ArticleId IdType="pubmed">25344523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hassenruck F, Knodgen E, Gockeritz E, Midda SH, Vondey V, Neumann L, et al.
Sensitive detection of the natural killer cell-mediated cytotoxicity of anti-CD20 antibodies and its impairment by B-cell receptor pathway inhibitors. Biomed Res Int
2018;2018:1023490.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5884282</ArticleId>
            <ArticleId IdType="pubmed">29750146</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bologna L, Gotti E, Manganini M, Rambaldi A, Intermesoli T, Introna M, et al.
Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. J Immunol
2011;186:3762–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21296976</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rafiq S, Butchar JP, Cheney C, Mo X, Trotta R, Caligiuri M, et al.
Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties. J Immunol
2013;190: 2702–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3631574</ArticleId>
            <ArticleId IdType="pubmed">23418626</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eichhorst BF, Busch R, Obwandner T, Kuhn-Hallek I, Herschbach P, Hallek M, et al.
Health-related quality of life in younger patients with chronic lymphocytic leukemia treated with fludarabine plus cyclophosphamide or fludarabine alone for first-line therapy: a study by the German CLL Study Group. J Clin Oncol
2007;25:1722–31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17389338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holzner B, Kemmler G, Kopp M, Nguyen-Van-Tam D, Sperner-Unterweger B, Greil R. Quality of life of patients with chronic lymphocytic leukemia: results of a longitudinal investigation over 1 yr. Eur J Haematol
2004;72:381–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15128416</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barrientos JC, O’Brien S, Brown JR, Kay NE, Reddy NM, Coutre S, et al.
Improvement in parameters of hematologic and immunologic function and patient well-being in the phase III RESONATE Study of ibrutinib versus ofatumumab in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma. Clin Lymphoma Myeloma Leuk
2018;18:803–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6527106</ArticleId>
            <ArticleId IdType="pubmed">30249389</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al.
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood
2008;111:5446–56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2972576</ArticleId>
            <ArticleId IdType="pubmed">18216293</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rawstron AC, Villamor N, Ritgen M, Bottcher S, Ghia P, Zehnder JL, et al.
International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia
2007;21:956–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17361231</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rawstron AC, Fazi C, Agathangelidis A, Villamor N, Letestu R, Nomdedeu J, et al.
A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. Leukemia
2016;30:929–36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4832072</ArticleId>
            <ArticleId IdType="pubmed">26639181</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ware JE, Gandek B, Group IP. The SF-36 Health Survey: development and use in Mental Health Research and the IQOLA Project. Int J Mental Health
1994;23:49–73.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
